Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models | Synapse
June 5, 2024Open Access
Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models
Key Points
Key points are not available for this paper at this time.
Abstract
Mitotic inhibition following treatment with eribulin and copanlisib by IHC in 3 eribulin-resistant PDX models